Journal article
Low-Molecular-Weight Heparin as Bridging Anticoagulation During Interruption of Warfarin: Assessment of a Standardized Periprocedural Anticoagulation Regimen
Abstract
BACKGROUND: The treatment of patients at increased risk for arterial thromboembolism who require temporary interruption of warfarin sodium therapy is a common clinical problem. We investigated the efficacy and safety of a standardized periprocedural anticoagulation regimen with low-molecular-weight heparin.
METHODS: We studied 650 consecutive patients with a mechanical heart valve, chronic atrial fibrillation, or embolic stroke who required …
Authors
Douketis JD; Johnson JA; Turpie AG
Journal
JAMA Internal Medicine, Vol. 164, No. 12, pp. 1319–1326
Publisher
American Medical Association (AMA)
Publication Date
June 28, 2004
DOI
10.1001/archinte.164.12.1319
ISSN
2168-6106
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AdultAgedAged, 80 and overAnticoagulantsAtrial FibrillationBiomarkersBlood Loss, SurgicalFemaleFibrinolytic AgentsFollow-Up StudiesHeart Valve DiseasesHeparin, Low-Molecular-WeightHumansInternational Normalized RatioIntracranial EmbolismMaleMiddle AgedPerioperative CarePostoperative ComplicationsProspective StudiesRisk FactorsSurgical Procedures, OperativeThromboembolismTreatment OutcomeWarfarin